MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative ¹⁷⁷Lu SPECT applied for Dosimetry of Radiopharmaceutical Therapy

Michael Ljungberg¹, Anna Celler², Mark W. Konijnenberg³, Keith Eckerman⁴, Yuni K. Dewaraja⁵ and Katarina Sjögreen-Gleisner¹

In collaboration with the SNMMI MIRD Committee: Wesley E. Bolch, A. Bertrand Brill, Fredric Fahey, Darrell R. Fisher, Robert Hobbs, Roger W. Howell, Ruby F. Meredith, George Sgouros, Pat Zanzonico

and the EANM Dosimetry Committee: Klaus Bacher, Carlo Chiesa, Glenn Flux, Michael Lassmann, Lidia Strigari, and Stephan Walrand.

¹Department of Medical Radiation Physics, Lund University, Lund, Sweden; ²Medical Imaging Research Group, Radiology Department, University of British Columbia, Vancouver, Canada; ³Department of Nuclear Medicine, Erasmus University Medical Center, Rotterdam, Holland; ⁴Easterly Scientific, Knoxville, Tennessee, USA; and ⁵Department of Radiology, University of Michigan Medical School, Ann Arbor, Michigan;

Corresponding Author: Michael Ljungberg, Ph.D. Professor Department of Medical Radiation Physics Clinical Science, Lund Lund University SE-221 85 Lund, Sweden Phone: +46 46 173565 Fax: +46 46 178540

Word count: 9881 (total in file)

ABSTRACT

Accuracy of absorbed dose calculations in personalized internal radionuclide therapy is directly related to the accuracy of the activity (or activity concentration) estimates obtained at each of the imaging time points. MIRD Pamphlet No. 23 presented a general overview of methods that are required for quantitative SPECT imaging. The present document is next in a series of isotope-specific guidelines and recommendations that follow the general information that was provided in MIRD 23. This paper focuses on 177-Lu (Lutetium) and its application in radiopharmaceutical therapy.

INTRODUCTION

The radionuclide ¹⁷⁷Lu (Lutetium) has been proven useful in a number of targeted radionuclide therapies because of its favorable decay characteristics and the possibility of reliable labeling of biomolecules used for tumor targeting. Initially, ¹⁷⁷Lu was used in a colloidal form for interstitial injections for sterilization of peri-tumoral lymph nodes (*1*). A second important clinical application of ¹⁷⁷Lu has been for peptide-receptor radionuclide therapy (PRRT) with DOTA⁰-Tyr³-octreotate (¹⁷⁷Lu-Dotatate) and other structurally related peptides. The PRRT use in treatment of neuroendocrine tumors (NETs) is motivated by the fact that the carrier peptide, octreotate, shows high-affinity binding to somatostatin receptors, which are overexpressed on the cell surface of many NETs (*2-6*). Furthermore, ¹⁷⁷Lu has been used in radioimmunotherapy clinical trials to label different kinds of monoclonal antibodies (*7-15*).

There is a growing body of evidence that radionuclide therapy should follow patient-specific planning protocols, similar to those that are being routinely used in external-beam radiation therapy. Recent literature reviews show correlations between absorbed dose and tumor response as well as normal-tissue toxicity (*16*). Such correlations indicate that treatments should be based on personalized dosimetry, aiming to deliver therapeutically effective absorbed doses to tumor(s), while keeping doses to organs at risk (OARs) below the threshold levels for deterministic adverse effects. In clinical PRRT studies, the primary adverse effects have been mainly renal and hematologic toxicities (*2,6,17*).

Although several studies have reported estimates of absorbed doses (4,7-9,12) for ¹⁷⁷Lu-Dotatate PRRT and ¹⁷⁷Lu RIT, the majority of these estimates have been based on planar imaging and conjugate-view activity quantification. Planar imaging, however, is known to have inherent limitations regarding the accuracy of activity quantification (*18*). As a result, an increasing number of clinical dosimetry protocols currently include ¹⁷⁷Lu SPECT/CT imaging studies (*15,18-20*) because of their superior accuracy. Comparisons of renal dose estimates in ¹⁷⁷Lu-Dotatate PRRT based on planar imaging and SPECT/CT, for example, have been reported (*18,21*) and are summarized in (*22*).

This document presents a set of guidelines outlining data acquisition protocols and image reconstruction techniques that are recommended for quantitative ¹⁷⁷Lu SPECT imaging. The guidelines are based on a review of the literature and are illustrated by the results of Monte Carlo simulations and phantom experiments, and by the examples of patient ¹⁷⁷Lu SPECT studies in which renal doses due to PRRT were estimated.

Decay of ¹⁷⁷Lu

¹⁷⁷Lu decays by β^- emissions to ¹⁷⁷Hf (Hafnium) with a half-life of 6.65 days (23). The maximum kinetic energy of ¹⁷⁷Lu β^- particles is 498.3 keV (24), and the mean kinetic energy of all this β^- decay is approximately 134 keV. Additionally, six groups of γ -photons and associated internal-conversion electrons are emitted. When considering all emitted electrons (β^- , conversion and Auger electrons) the mean kinetic energy rises to 147 keV. Two of these γ photons, with the energies of 112.9 keV (6.17%) and 208.4 keV (10.36%), have been successfully used in ¹⁷⁷Lu imaging studies. Table 1 summarizes information about ¹⁷⁷Lu γ -photon energies and intensities based on (*23-29*). Moreover, bremsstrahlung radiation generated by interactions of β -particles with tissue may be observed. Bremsstrahlung yield, however, is very low (0.012 bremsstrahlung photons per decay for a ¹⁷⁷Lu source in water (unpublished data)) and the majority (~85%) of these photons have energies below 50 keV. Nevertheless, some of them can contribute to the background recorded in the low-energy part of the spectrum.

DATA ACQUISITION

The choice of collimator in imaging studies is a trade-off between the need for high system sensitivity to achieve good signal-to-noise ratio (SNR) and spatial resolution in images, and the need to minimize septal penetration of highenergy photons. If the collimator septa are not thick enough, a large number of photons that penetrate or scatter in the collimator septa will be detected, resulting in decreased image contrast, degradation of spatial resolution and increased image artifacts, leading to difficulties in accurate activity distribution quantification.

Table 2 illustrates these issues by comparing system sensitivities (cps/MBq) for imaging studies performed using the 113-keV and 208-keV photopeaks. The

data in this table represent sensitivities per camera detector calculated using Monte Carlo simulations (*30*) and 20% energy windows centered at 113 keV and 208 keV. Four types of collimators of the Infinia[™] family of collimators (GE Healthcare) and two NaI(Tl) crystal thicknesses were investigated. The modeled source was a 10-cm diameter ¹⁷⁷Lu Petri-like disc placed in air at 10 cm from the collimator surface. Additionally, for each case in parentheses the fractions of the detected counts due to collimator scatter and septal penetration are shown.

Although in general the system sensitivity is higher for low-energy generalpurpose (LEGP) or low-energy high-resolution (LEHR) collimators than for medium-energy (ME) or high-energy (HE) collimators, ME collimators are preferable for ¹⁷⁷Lu imaging because of their lower septal penetration of the high-energy photons emitted by ¹⁷⁷Lu. On the other hand, although high-energy collimators (HE) have slightly better sensitivity than ME collimators for 208keV photons, they have inferior spatial resolution due to their wider collimator holes.

For 208-keV photons, a thicker 5/8" scintillation crystal provides higher sensitivity than the standard 3/8" crystal which decreases the statistical noise in the image for any given acquisition time and activity. For example, for a 5/8"thick crystal thickness, the number of photons detected in a 20% energy window centered at 208 keV increases by about 35% as compared to that for a 3/8"-crystal. Note, however, that the sensitivity for the 113 keV window is higher for the 3/8"-crystal as compared to the 5/8"-crystal as a result of contribution from 208-keV photons that have been back-scattered in the material behind the crystal. The energy of 208 keV photons scattered at 180° is 114.6 keV. For a thinner crystal, the probability of a 208 keV photon passing through the crystal increases, thereby increasing the contribution from back-scatter. Also the high-energy photons from the ¹⁷⁷Lu decay can back-scatter and contribute to the image counts.

If a ME collimator is used, the data should be collected in a 15-20% energy window centered on the 208-keV photopeak. If the number of count collected in the 208-keV window is considered insufficient, a second energy window centered on the 113-keV photopeak can be used. It is recommended that the two datasets be acquired into separate projection files and reconstructed into two separate images (each image individually compensated for attenuation and scatter using appropriate attenuation maps). Only when the quality of the images obtained from the lower-energy projections is deemed acceptable (i.e. the images obtained from the 113-keV window have a similar image appearance as those from the 208-keV window), should they be summed for further analysis.

If employing a low-energy collimator (LEHR or LEGP), a single 20% energy window centered on the lower 113-keV photopeak is preferable, as in this case the contribution from septal penetration severely deteriorates the image acquired in the 208-keV photopeak window (*31*). However, in the 113-keV energy window a significant portion of the acquired counts will originate from the high-energy photons that have scattered in the patient and the collimator.

This effect can be seen in the data presented in Table 2. These scattered photons considerably increase the background in the 113-keV photopeak energy window. Thus, accurate scatter correction becomes essential.

These effects are visualized in Figures 1-3. The data presented in these figures were generated using Monte Carlo simulations (*30*) of a SPECT system with a 5/8" NaI(Tl) crystal, and energy resolution with FWHM of 9.5% at 140 keV. The patient was simulated using an XCAT digital male phantom (*32*), with activity distribution based on a typical patient imaging study performed 24 h after an injection of 7.4 GBq ¹⁷⁷Lu-Dotatate.

Figure 1 compares energy spectra of the detected photons for LEGP and ME collimators. Although both spectra correspond to the same source activity, their shapes and count rates are very different. Both spectra have high scatter background in the lower-energy region. However, due to collimator septal penetration, in the spectrum acquired with the LEGP collimator the 208-keV photopeak has a significantly higher count rate than the 113 keV photopeak, despite similar decay intensities of these two transitions (Table 1). Not only is the count rate of the 208-keV photopeak about 4 times higher than that of the 113-keV photopeak, but also some lower-abundance higher-energy photopeaks, such as 249.7-keV and 321.3-keV, are clearly visible. In the spectrum acquired with the ME collimator (with its thicker septa and therefore less septal penetration) the measured intensities better reflect the true emission rates. To further illustrate the negative effect of septal penetration on image quality,

Figure 2 displays four projections simulated for these two collimators (LEGP

and ME) and for the two energy windows (113 and 208 keV). In order to better visualize the penetration effect the simulation did not include scatter and attenuation in the phantom. These data suggest that the ME collimator provides the best image quality for both energy windows and is therefore more suitable for use in imaging.

In addition to the penetration effect, the contributions from photons scattered in the patient also influence both image quality and our ability to quantify activity. To illustrate this additional unwanted scatter contribution, Figure 3 shows simulated anterior projection images (33) obtained using the ME collimator. Figure 3A represents an idealized imaging situation when the spatial resolution is perfect (i.e. the simulation does not include blurring due to detector spatial resolution and collimator response), photons pass unscattered from the site of decay to the detector and deposit their full energy in the crystal. The 208-keV energy window was used for this image. Figures 3B and 3C represent realistic images that include effects of limited collimator resolution (collimator blurring) and scatter and attenuation in the object for energy windows centered at 113 keV and 208 keV, both with window widths of 20%. Figure 3B shows that the image acquired in the 113-keV energy window had a higher background of scattered photons and decreased image contrast as compared with Figure 3D, which corresponds to the 208-keV window. Figure 3D shows the sum of the data obtained in these two energy windows.

Additionally, based on these simulations, the scatter-to-total (S/T) ratios for the whole projection, that is, the fractions of detected photons that have been

scattered in the phantom to the total number of detected events, were estimated. Simulations were performed for two crystal thicknesses, two photopeak energy windows settings, four collimators, and for acquisitions using separately each of the ¹⁷⁷Lu photopeaks and a combination of both. The results are presented in Table 3.

Examination of the values summarized in Table 3 shows that, when using the 208-keV energy window, the S/T ratio in most cases was in the range of 0.17 to 0.27, with values slightly lower for higher crystal thicknesses. This ratio was much higher, however, and equaled about 0.47-0.60 for the 113-keV energy window. This increase was partly caused by the increased detection of self-scattered 113-keV photons, but mostly was due to a large contribution of down-scattered 208-keV photons into this window. The S/T slightly improved with a 15% energy window, and depended only weakly on the crystal thickness. Thus, when using a 113-keV window it is important to use a reliable scatter correction method to compensate for this large scatter fraction.

For ¹⁷⁷Lu SPECT, acquisition in 128 × 128 projection matrices is advisable if the count rates allow for it (*34*). Auto-contour orbits should be used to get the best possible image resolution. The use of auto-contouring also makes acquisition preparation easier and thereby improves the overall efficiency of the patient study. Clinical ¹⁷⁷Lu SPECT imaging studies using 60-120 projection angles have been reported (*18,20,21*).

DATA PROCESSING

Filtering

The need for low-pass filtering of the projection data may arise if the count levels resulting in high image noise are observed. In order to avoid bias in the activity determination, the user should verify that the total counts in the data (in the projections or in the reconstructed image) remains unchanged after filtering.

Please note, that if a collimator-detector response (CDR) compensation is applied during the reconstruction, this compensation changes the noise texture in the image which may make pre-/post-reconstruction low-pass filtering unnecessary. However, the decision about filtering should be based on the specific objectives of the study (*35,36*).

Dead Time

Although in principle, in radionuclide therapy imaging the count losses related to dead-time (DT) effects can be substantial, in ¹⁷⁷Lu imaging, the DT effects are actually rather small (even for high activities) because of the low yield of γ -photons emitted in the decay of ¹⁷⁷Lu and the very small bremsstrahlung contribution. For ¹⁷⁷Lu-Dotatate patients, it is mainly scans performed shortly after the therapeutic injection, that can be affected by DT losses, especially if the urinary bladder is included in the FOV. However, even if the DT effects are

modest, care must be taken to estimate them, especially for scans performed shortly after the therapeutic injection.

The count losses due to DT estimated from the entire spectrum can be significantly lower (by a factor of 2 or more (37)) than when only count losses in the photopeak window are considered. This is because the pile-up effects change the distribution of counts in the spectrum. When a new scintillation event occurs before the light from previous events has decayed, the recorded energy will be higher than expected. As a result, some counts are shifted from the photopeak region, but still are recorded in the high-energy part of the spectrum (38). The spatial localization of the event can also be affected, since the x,y coordinates are determined from the centroid of the scintillation light emission. There is also a possibility for scattered photons to pile-up in the photopeak window, especially for lower-energy window locations, such as the 113-keV window, where the separation in energy between scattered and primary photons is smaller. Therefore, since images are reconstructed from the photo peak counts only, the determination of the DT correction factor should be parameterized based on the counts recorded in the whole spectrum, but only the count losses in the photopeak window should be described.

One way of addressing the DT problem is to perform a series of phantom experiments with gradually decaying activity, using the same acquisition protocol and scatter correction as used for patient studies. Analysis of count losses in these phantom images can be used to establish DT correction factors as a function of count rate for any particular camera system. In this type of DT measurements, it is recommended to use a phantom that as closely as possible models an "average patient" in both size and activity distribution.

As an alternative to the phantom-based estimation of DT losses, the DT correction factor could be estimated from planar imaging performed in conjunction with the patient SPECT scan. In this method, a small marker source is be placed at the edge of the FOV of the camera and planar scans over the SPECT FOV with and without the patient (39) are be performed. The ratio of counts from these two scans (obtained from data acquired in the photopeak window and corrected for scatter) in a region of interest (ROI) around the marker provides the DT correction factor to be used for patient studies. The drawback of this method is the additional acquisition time required for these planar scans (with and without the patient). It has been suggested (40) that the DT correction factor can be determined using a 5-10 min planar patient scan performed in close connection to the tomographic acquisition. The DT correction factor can also be determined from multiple projection views (41). As the dead time will very likely affect only scans performed shortly after injection (the first time point in the time-activity curve), it may have little effect on the overall absorbed dose calculation because of the relatively small contribution of this first time point to the cumulated activity.

Iterative Reconstruction

Accurate quantification requires compensation for image degrading factors. Iterative reconstruction methods, such as the maximum likelihood expectation maximization (MLEM) algorithm (42) and the ordered subsets expectation maximization (OSEM) algorithm (43) provide the ability to compensate for these effects in a unified manner, and are thus typically used and are recommended (34).

Iterative methods require a certain number of updates before reaching an acceptable image quality. This then implies the for a criterion to determine the number of iterations used. MIRD Pamphlet 23 (*34*) defines the convergence as when the 90% recovery has been reached this states to be a level of "high reconstruction accuracy". A general 'rule-of-thumb' is that more complex reconstruction problems (where more corrections are included in the algorithm) require a larger number of iterations to reach convergence. It is important to investigate this dependency and optimize reconstruction parameters using data from phantom studies and simulations but also sample patient data with representative activity distributions and counting statistics.

The number of iterations required for convergence for a given number of subsets also depends on the organ size. Figure 4 illustrates this effect using an example of the reconstruction of a ¹⁷⁷Lu Dotatate patient SPECT/CT scan. The total activity in volumes of interest (VOIs) drawn around the kidneys and a tumor is plotted as a function of the number of OSEM updates (number of subsets multiplied by number of iterations). Since the true activity is not known

in this case, the curves have been normalized to the highest activity value obtained for each VOI. For this particular case, the volume of the tumor was similar to that of the kidneys. It can be seen that a smaller number of iterations was required for convergence for the kidneys than for the tumor. The slope of the tumor curve diminishes earlier than that for the kidneys, but after 200 updates when the kidneys show convergence the tumor still shows an upward trend to the maximum value. If following the 90% of maximum activity as being a measure for recovery the tumor reaches this level at 20 updates whereas the right kidney needs 40 updates. For 95%, however, all VOIs reach this level at 60 OSEM updates.

In general, since image noise tends to be amplified as the number of iterations increases, when interpreting data derived from SPECT images (for example, by using dose-volume histograms), it is important to remember that high variations in voxel counts may be caused by the reconstruction process and may not necessarily be related to a heterogeneous biological uptake of the radiopharmaceutical.

PHOTON ATTENUATION

The most important factor altering the number of photons that impinge on the gamma camera detector is photon attenuation. The thickness of tissue-equivalent material that reduces the fluence of 208 keV photons to half is only about 5 cm. Since this attenuation depends on the density of the medium, an

accurate attenuation correction must be based on patient-specific attenuation maps (34).

How attenuation maps (AM) used for attenuation correction (AC) are determined depends on the camera system but, if possible, it is recommended that a CT study is used for this purpose, preferably acquired using a SPECT/CT camera.

The accuracy of image quantitation critically depends on the accuracy of attenuation coefficients that are input into AC. Therefore, when using CT-based AM accurate translation of CT images from Hounsfield numbers to attenuation coefficients corresponding to the energies of the ¹⁷⁷Lu photopeak(s) must be performed. Additionally, since CT and SPECT data use different matrices and voxel sizes, the CT images must be properly registered to align with SPECT images, and interpolated to match SPECT matrix sizes. Finally, AM should be smoothed so that their resolution matches the SPECT resolution in order to reduce potential edge effects at boundaries, in regions displaying large attenuation gradients (such as those at soft tissue/air, lung/soft tissue and soft tissue/bone interfaces). As a result, creation of AM from CT images is a complex procedure, requiring proprietary information about both CT and SPECT systems, it is therefore recommended that attenuation maps reconstructed using manufacturer's software are used.

If both 208-keV and 113-keV photopeaks are used for imaging, two separate AM must be generated and images reconstructed.

Given the importance of AC, a quality control (QC) protocol must be developed to ensure that the AM reflects correct attenuation coefficient values for the major classes of tissues (lungs, tissue and bone). Additionally, the accuracy of the alignment of the attenuation map and SPECT image must be checked because CT and SPECT scans are always performed sequentially and the patient may move between and/or during scans (*44*).

COMPTON SCATTER

Each photopeak energy window will also contain events from scattered photons (45), as shown in Table 3. For ¹⁷⁷Lu studies, this will include both self-scattered photopeak photons (i.e. scattered photons that initially had the energy equal to the photopeak energy of the considered energy window) and down-scattered photons from high-energy transitions.

The use of scatter correction is especially important for 113 keV-based imaging because of the large contribution from down-scattered high-energy photons in this window.

A practical correction technique is the triple-energy-window (TEW) method (46). Two additional windows, set on both sides of the photopeak, allow the user to account not only for the self-scatter but also for down-scattered high-energy photons. The compensation method can be described by

$$SE_{pw} = \left(\frac{C_{lw}}{W_{lw}} + \frac{C_{uw}}{W_{uw}}\right) \cdot \frac{W_{pw}}{2}$$
(1)

where: C_{lw} and C_{uw} are pixel counts in lower and upper windows, respectively, and W_{lw} , W_{uw} and W_{pw} are the respective widths of lower, upper and photopeak windows. The windows widths must be carefully selected, since too narrow windows will result in a high noise level in the scatter image (47). Usually energy windows are selected to have the width (in percent) equal to one-half of the width (48) or the same width (31,49) as the photopeak window, unless another photopeak prevents it. Such situation occurs, for example, if a scatter energy window is to be set below the 113-keV photopeak, where Pb X-ray photons may interfere.

Subtraction pixel-by-pixel of estimated scatter projections from the photopeak projection image results in noise amplification or even negative counts (*50*). Better results are obtained when the scatter estimate is incorporated into the projector step in the iterative reconstruction algorithm. Additionally, since for a ME collimator the scatter energy window set above the 208-keV photopeak usually contains relatively few counts, this second scatter window can be ignored (*47,48*).

For the majority of ¹⁷⁷Lu studies applying the TEW scatter correction will result in relatively good quantitative accuracy of activity distributions. This is because window-based correction method compensates not only for the selfscattered photons, but also for the "background" beneath the photopeak that is created by scattered high-energy photons. Thus, reasonably accurate quantitative images can be reconstructed from studies performed with low energy collimators and 113-keV photopeak or ME collimators and 208 keV only or ME collimators and both photopeaks.

However, the scattered photons recorded in the lower energy window originate from different locations than those in the photopeak window. Moreover, many of the scattered high-energy photons recorded in the scatter window may have scattered several times before being detected. For these reasons, the TEW correction does not accurately reproduce the distribution of scattered photons in the photopeak window, particular in regions with non-uniform density distributions. This effect is illustrated in Figure 5, which compares projection images (A) and (C) of the true distributions of scatter in 208-keV and 113-keV energy windows, respectively, with the corresponding TEW-estimated scatter images (B) and (D). The true scatter images are sharper than those obtained with the TEW method. However, these differences are usually small, especially in the abdomen region illustrated in this figure; they are mostly smaller than 10%.

Scatter compensation can also be performed using a direct modeling of scatter in the projector step of the reconstruction method. For instance, the effective scatter source estimation (ESSE) method, developed by Frey *et al.* (*51,52*), uses pre-calculated kernels obtained from Monte Carlo simulations to estimate selfscatter in the photopeak window, while the analytical photon distribution interpolative (APDI) method (*53*,*54*) uses the Klein-Nishina cross-section for Compton scattering to analytically calculate scatter distribution in projections. For situations when the density distribution is non-uniform improved image quality and quantitative accuracy can be obtained if scatter models, such as the ESSE or APDI, are used. Both the ESSE and APDI methods have been successfully applied to ¹⁷⁷Lu phantoms studies (*31*,*47*).

COLLIMATOR-DETECTOR RESPONSE

The collimator-detector blurring, which affects the spatial resolution of the image, varies with the source-to-collimator distance (*34*). For LEHR and ME collimators typical spatial resolutions of the system measured at 10 cm are about 8 mm and 10 mm, respectively. Additionally, septal penetration and scatter in the collimator can further reduce image contrast and spatial resolution. (see Table 2).

Reconstruction algorithms, that include geometric collimator-detector response (CDR) compensation, modify the distribution of counts in the image but do not change their total number. Therefore, they do not affect the quantification of the total activity in the field-of-view. CDR compensation not only improves spatial resolution, but also changes the noise texture so that the image appears smoother. The improvement depends in a complex way on the signal-to-background ratio, noise levels in the data, camera orbit and the number of iterations. When quantify the total activity in an organ or tumor, a

reconstruction with CDR compensation may be beneficial since it decreases the resolution-induced spill-out of counts from hot regions.

However, CDR compensation may create Gibbs-like artifacts (ringing artifacts) in the vicinity of sharp boundaries (55) and thereby change the distribution of counts within a VOI. When the distribution of absorbed doses for individual voxel locations is calculated within a VOI for further analysis using dose-volume histograms, one should be aware of the fact that CDR correction may result in creation of false dose-volume information (*36*).

Figure 6 illustrates four types of reconstructed images of the kidney region. The image in Figure 6d corresponds to the one used clinically in the Lund protocol described in detail in the Patient Example section. Images (a-c) are displayed to show the impact of different compensation methods on image quality.

ACTIVITY QUANTIFICATION

Camera Calibration

Reconstructed images represent the 3D distributions of voxel values obtained by measuring photons emitted from the imaged object. To convert voxel values to activity, the camera system must be carefully calibrated using a radioactive source with a well-determined ¹⁷⁷Lu activity (*45*). Furthermore, it is important to ensure that the activity meter (dose calibrator) used to measure the activity of ¹⁷⁷Lu calibration source is correctly calibrated with a well-known (i.e. independently calibrated) ¹⁷⁷Lu activity, preferably one that is traceable to a standard laboratory. Care must also be taken that the same source geometry (same vials and the same volume of activity-containing solution) are used in these measurements as will be used for clinical studies, as the dose calibrator measurement is source-geometry dependent.

Different approaches can be used to determine the camera calibration factor, depending on how accurately attenuation and scatter corrections are implemented (34). If corrections are accurate (i.e. the reconstructed image truthfully represents the distribution of emitted photons), calibration can be performed by simply acquiring a planar image of a small point-like source placed in air. The calibration factor for the camera (cps/MBq)FOV is then determined from the total counts in a ROI surrounding the source image, divided by the acquisition time and activity. However, potential contribution to the ROI from the high-energy ¹⁷⁷Lu scattered photons may need to be accounted for (by using appropriate scatter correction method e.g. TEW) (56). Alternatively, a large water cylinder containing a well-calibrated source of ¹⁷⁷Lu can be scanned. The same acquisition protocol and reconstruction method (with corrections) as used in patient studies must be employed. Again, the calibration factor is then determined by dividing the total counts in the reconstructed image of the phantom by the scan time and activity. These two methods, namely, planar acquisition of a small source and tomographic scanning of a extended source, should ideally result in the same calibration factor (56).

Quantification of activity in VOIs

In radionuclide therapies with ¹⁷⁷Lu-Dotatate, because kidneys are considered to be the main organ at risk, the renal absorbed dose is of interest. When using a SPECT/CT system with high-resolution CT, the kidney VOI can be drawn using anatomical images from the CT part of the study. However, due to activity spill-out resulting from partial volume effects (PVEs) (*34*), the kidney activity determined from the volumes obtained from CT will be underestimated. PVEs also blur the boundaries of regions making determination of their exact location difficult, thus imposing uncertainties on activity measurements. The CDR incorporated into the reconstruction algorithm reduces the spill-out to some extent, making it easier to determine the activity content of a VOI. However, it is important to be aware of the artifacts that may be introduced by CDR in the form of "rims" with increased activity (Gibbs artifacts).

Several software-based methods have been proposed to correct for PVEs, (55) but in the majority of cases their implementation in routine clinical practice is limited by their complexity. Probably the simplest and commonly used method is to apply experimentally determined recovery coefficients, *RC*s, as described in (*34*). For patient studies, the activity Avoi contained in a VOI is then determined as a product of three parameters, according to

$$A_{VOI} = CPS_{VOI} \cdot \frac{1}{RC_{OBJ}} \cdot \frac{1}{\left(\frac{CPS}{MBq}\right)_{FOV}}$$
(2)

where the first parameter CPS_{VOI} is the count rate measured in an image VOI, the second parameter RC_{OBJ} is the recovery coefficient for an object which best represents the VOI dimensions in the patient image and the third parameter is the system sensitivity (cps/MBq). An example of a recovery coefficient curve for ¹⁷⁷Lu determined using a series of spheres with different sizes placed in a phantom has been described by Ilan *et al.* (*57*). It should be pointed out that the values of RCs not only depend on the object size and shape, but also are strongly influenced by data acquisition protocol and image reconstruction method, so RCs need to be determined for each camera/collimator and data acquisition/reconstruction protocol.

Time-activity curves

Quantitative information about temporal changes in activity distribution is required for determination of time-activity curves (TACs) and time-integrated activity concentrations (*34*). If it is not possible to perform SPECT acquisitions at multiple time points (due to time constraints, for example), a hybrid planar/SPECT approach is sometimes used (*34*). Here, the TACs are determined from a time-series of planar whole-body scans that have been corrected for attenuation, scatter and over-lapping activity contribution. At one time point, an additional quantitative SPECT study is also performed. Each TAC is then rescaled by the ratio of activities determined for the organ/region corresponding to this TAC from the SPECT image and the whole-body (i.e. planar) study.

PHANTOM IMAGING STUDIES

In patient studies, the evaluation of quantitative accuracy of reconstructed images is extremely difficult (if not impossible) because in this case true values of activity are not known and usually cannot be independently determined. However, such evaluation can be done using phantom experiments. Therefore, although it is generally acknowledged that even the most sophisticated phantoms are not able to reproduce the complexity of activity and tissue distributions encountered in patients, phantom experiments are often used to determine the accuracy of imaging methods. Additionally, in order to compare and combine image-derived absorbed dose values obtained at different centers (possibly using different camera systems, imaging protocols and reconstruction algorithms), phantom studies are recommended for cross-calibration.

Several issues related to quantitation of ¹⁷⁷Lu imaging studies have been investigated using phantom experiments. These include comparison of different approaches to determine camera normalization factors (*56*), investigation of dead-time effects and appropriate correction methods (*40,48*), and comparison of the accuracy of image quantitation which can be achieved when using 113-keV and/or 208-keV photopeaks for the camera equipped with LEHR and ME collimators (*31,48*).

In particular, to evaluate accuracy of image quantitation, experiments with spherical and cylindrical objects filled with ¹⁷⁷Lu activity placed in air and in water without and with background activity have been performed. Image reconstructions used OSEM algorithms with CDR compensation available on

commercial cameras (48) or reconstruction methods developed in-house (31). All reconstructions used CT-based attenuation correction, while for scatter correction the dual-energy window method (DEW) (31,48), TEW (47,58), ESSE (47) and APDI (31) methods were investigated. Table 4 summarizes the results of these studies.

CLINICAL APPLICATIONS OF ¹⁷⁷Lu

In early animal experiments it was shown that after injection the ¹⁷⁷Lu salts transform to hydroxide and form colloids, which are cleared by phagocytosis to regional lymph nodes (*1*). Animal biodistribution studies have demonstrated that approximately 60% of soluble ¹⁷⁷Lu salts circulating in the blood stream will concentrate in the skeleton resulting in high absorbed doses (*59*).

Presently, ¹⁷⁷Lu is used in PRRT for treatment of NETs, in some cases parallel to or in conjunction with ⁹⁰Y. In the majority of centers Dotatate and/or Dotatoc are employed and all patients are injected with the same 7.4 GBq activity repeated in 4-6 therapy cycles. Clinical PRRT trials show favorable outcomes in terms of progression-free survival and overall objective response rate (2,6,17). However, improved treatment outcomes could be expected if the injected activities would be based on personalized dosimetry calculations and image-based therapy plans.

Personalized dosimetry in PRRT aims to determine the maximum administered activity that will result in an absorbed dose that will be well tolerated by the patient with little or no side effects of renal and hematologic toxicities (2, 17). Kidney irradiation is usually prolonged due to tubular reabsorption of radiolabeled peptides and therefore co-infusion of amino acids is often performed for renal protection. Using ¹⁷⁷Lu-Dotatate, permanent renal toxicity has been considerably less frequent compared to that for ⁹⁰Y-Dotatoc (3, 17).

The limits for absorbed dose to the kidneys have been set at either 23 Gy (20,60) or 27 Gy (18,61). The use of the biologically effective dose (BED) allows for comparisons of therapies using different number of cycles and other radionuclides like ⁹⁰Y. Based on these studies new kidney dose limits of 28 Gy and 40 Gy (depending on the presence of additional risk factors) have been proposed (4). A study from Uppsala (20) showed that only 20% of patients reached the lower 23-Gy threshold after 3 cycles of 7.4 GBq and that 50% of the patients were treated using more than 4 cycles. These results clearly indicate that a standard protocol of 7.4 GBq administered activity in 4 cycles may lead to an under-treatment for a large groups of patients, as the maximum therapeutic response rate (i.e. the combination of percentage of patients showing partial and complete response after therapy) by 177 Lu is 35% (2,17). Personalized dosimetry may allow for better tailoring of the administered ¹⁷⁷Lu activity and/or the number of treatment cycles to the needs of each individual patient.

PATIENT EXAMPLES

Individualized dosimetry-based treatment planning in ¹⁷⁷Lu-Dotatate PRRT has been reported separately by both Uppsala Academic Hospital and Lund University Hospitals (*18,20,21*). Currently, a clinical study is ongoing in collaboration between Lund and Sahlgrenska University Hospital, Gothenburg, Sweden. Details of these clinical studies provided in the following section exemplify two different approaches to clinical quantitative ¹⁷⁷Lu SPECT imaging of patients having treatment cycles of 7.4 GBq administered with concomitant infusion of an amino-acid solution for renal protection.

Uppsala reported dosimetry evaluations in a regimen where subsequent treatment cycles were given until either a) the total absorbed dose to the kidneys reached 23 Gy or b) the bone marrow dose reached 2 Gy (20,62). Tumor absorbed doses were also evaluated in (57). In the routine protocol absorbed doses to kidneys and other organs were determined from the SPECT/CT imaging performed during the first treatment at 24 h, 96 h, and 168 h post-administration, and one SPECT/CT study at 24 h in the following cycles. The SPECT/CT acquisitions were performed using ME collimators and 120 projection angles with acquisition time equal to 30 sec per frame. An energy window of 20% was centered on the 208-keV photopeak, and projection data were stored in 128×128 matrices. SPECT reconstruction was performed using software available on the clinical workstation. An iterative OSEM algorithm with 4 iterations and 8 subsets and post-filtering using a Hann filter with a cutoff of 0.85 were used (20,62). Attenuation correction based on a low-dose CT image was included in the reconstruction, but corrections for scatter and collimator response were not included. SPECT image calibration was implemented by imaging a 100-mL¹⁷⁷Lu sphere placed inside an elliptical

water-filled cylinder. The count rate in a spherical 4 cm³ VOI placed centrally in the sphere in the reconstructed image was determined and the activity concentration in kidneys was quantified using this VOI. A mono-exponential function was fitted to the three data points to determine the cumulated activity concentration. Absorbed dose was calculated by multiplying the time-integrated activity concentration by the dose concentration factor, derived from the unit density sphere model of ¹⁷⁷Lu (*63*) and thus taking self-dose into account (*21*).

In the Lund/Gothenburg ongoing clinical trial (EudraCT no. 2011-000240-16), treatment continued until the total delivered renal BED dose reached 27 Gy, or 40 Gy, depending on additional risk factors (4). Dosimetry was performed during every treatment cycle and was based on a hybrid SPECT/planar method, chosen as a compromise between the quantitative accuracy of SPECT and the need to visualize the whole-body tumor burden during the course of treatment. The SPECT/CT scan were acquired at 24 h post injection, using 60 projections, each of 45 s, in a 360-rotation mode. Acquisitions were performed using a single energy window centered on the 208-keV photopeak with a width of 15% or 20%, depending on the energy resolution of the SPECT/CT systems used. ME collimators were employed, and projection data were stored in 128×128 matrices. The whole-body anteriorposterior planar imaging was performed at 0 h, 24 h or 48 h, 96 h, and 168 h post-injection. The acquired images were exported for further processing using the in-house software LundAdose (64). The renal TACs were determined from

this series of planar images that were corrected for attenuation, scatter and overlapping tissues activity (*18,65*). SPECT reconstruction was performed by an iterative OSEM algorithm with 8 iterations and 10 subsets. Corrections for attenuation, scatter and collimator response were included in the reconstruction, with the low-dose CT image used to generate attenuation maps and scatter kernels for the ESSE method (*51*) pre-calculated using Monte Carlo methods (*30*).

Camera calibration for both SPECT- and planar-based quantification was derived from a planar scan of a known activity placed in a Petri dish in air. From the quantified SPECT images maps of the absorbed dose rate were calculated using a Monte Carlo-based method where a CT-derived 3D map of the tissue density distribution was used as an input (*66*). VOIs encompassing the cortex and medulla of the left and right kidneys were manually segmented based on the CT images. The absorbed dose rates were determined as the median values of activity within these VOIs, which were compensated for partial-volume effects using a recovery factor of 0.85, as determined experimentally. These SPECT-derived absorbed-dose rates were used to renormalize the TACs obtained from planar images, giving time-versus-dose rate curves from which values of the absorbed doses were calculated (*67*).

SUMMARY

There is a growing body of evidence that effectiveness of targeted radionuclide therapies could be greatly improved if they followed personalized plans based on patient-specific dosimetry calculations (*16*). Such calculations, however,

require accurate information about the biodistribution of the radioactive therapeutic agent in the patient body, which must be obtained from quantitative imaging studies.

While the medium-energy beta emissions of ¹⁷⁷Lu make it very useful for many radionuclide therapy applications, its gamma emissions are suitable for quantitative imaging necessary for dosimetry calculations. This document, which follows the general overview of quantitative imaging principles to be used in radionuclide therapy studies presented in (*34*), describes methods which are specifically recommended for use in ¹⁷⁷Lu quantitative studies. A detailed discussion of the effects that can affect the quantitative accuracy of the estimated activity distribution, and a series of recommendations and guidelines are provided. The discussed effects and recommendations are illustrated by example images and are supported by numerical data obtained from simulations, phantom experiments, and patient studies.

DISCLOSURE

The authors have no disclosures.

ACKNOWLEDGEMENTS

Support was granted by the Swedish Research Council, the Bertha Kamprad Foundation and the Gunnar Nilsson Cancer Foundation.

REFERENCES

1. Kyker GC, Christopherson WM, Berg HF, Brucer M. Selective irradiation of lymph nodes by radiolutecium (Lu 177). *Cancer*. 1956;9:489-498.

2. Kwekkeboom D, de Herder W, Kam B, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. *J Clin Oncol.* 2008;26:2124-2130.

3. Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. *J Clin Oncol.* 2011;29:2416-2423.

4. Bodei L, Cremonesi M, Ferrari M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. *Eur J Nucl Med Mol Imaging*. 2008;35:1847-1856.

5. Kam BL, Teunissen JJ, Krenning EP, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. *Eur J Nucl Med Mol Imaging*. 2012;39:S103-112.

6. Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. *European Journal of Nuclear Medicine and Molecular Imaging*. 2015 42:5-19.

7. Forrer F, Oechslin-Oberholzer C, Campana B, et al. Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas. *J Nucl Med.* 2013;54:1045-1052.

8. Stillebroer AB, Zegers CM, Boerman OC, et al. Dosimetric analysis of 177-Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging. *J Nucl Med.* 2012;53:82-89.

9. Vallabhajosula S, Goldsmith SJ, Hamacher KA, et al. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. *J Nucl Med.* 2005;46:850-858.

10. Meredith R, You Z, Alvarez R, Partridge E, Grizzle W, LoBuglio A. Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer. *Cancer Biother Radiopharm.* 2012;27:36-40.

11. David KA, Milowsky MI, Kostakoglu L, et al. Clinical utility of radiolabeled monoclonal antibodies in prostate cancer. *Clin Genitourin Cancer*. 2006;4:249-256.

12. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. *J Clin Oncol.* 2005;23:4591-4601.

13. Tagawa ST, Milowsky MI, Morris M, et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. *Clin Cancer Res.* 2013;19:5182-5191.

14. Schoffelen R, Boerman OC, Goldenberg DM, et al. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results. *Br J Cancer*. 2013;109:934-942.

15. Schoffelen R, Woliner-van der Weg W, Visser EP, et al. Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer. *Eur J Nucl Med Mol Imaging*. 2014;41:1593-1602.

16. Strigari L, Konijnenberg M, Chiesa C, et al. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. *Eur J Nucl Med Mol Imaging*. 2014;41:1976-1988.

17. Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. *Eur J Nucl Med Mol Imaging*. 2014.

18. Garkavij M, Nickel M, Sjögreen-Gleisner K, et al. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors:

Analysis of dosimetry with impact on future therapeutic strategy. *Cancer Biother Radiopharm.* 2010;116:1084-1092.

19. Guerriero F, Ferrari ME, Botta F, et al. Kidney dosimetry in 177Lu and 90Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors. *Biomed Res Int.* 2013;2013:935351.

20. Sandstrom M, Garske-Roman U, Granberg D, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. *J Nucl Med.* 2013;54:33-41.

21. Sandstrom M, Garske U, Granberg D, Sundin A, Lundqvist H. Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. *Eur J Nucl Med Mol Imaging*. 2010;37:212-225.

22. Cremonesi M, Ferrari M, Di Dia A, et al. Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy. *Q J Nucl Med Mol Imaging*. 2011;55:155-167.

23. Kondev FG. Nuclear data sheets for A = 177. *Nuclear Data Sheets*. 2003;98:801-1095.

24. Deepa S, Vijay Sai K, Gowrishankar R, Rao D, Venkataramaniah K. Precision electron-gamma spectroscopic measurements in the decay of 177Lu. *Appl Radiat Isot.* 2011;69:869-874.

25. Schotzig U, Schrader H, Schonfeld E, Gunther E, Klein R. Standardisation and decay data of 177Lu and 188Re. *Appl Radiat Isot*. 2001;55:89-96.

26. Kossert K, Nahle OJ, Ott O, Dersch R. Activity determination and nuclear decay data of 177Lu. *Appl Radiat Isot.* 2012;70:2215-2221.

27. Eckerman KF, Endo KFEA, Endo A. *MIRD: Radionuclide data and decay schemes*: Society of Nuclear Medicine; 1989.

28. Kondev FG. Table of radionuclides. In: Be' MM, Criste' V, Dulieu C, et al., eds. Vol 2; 2004:107-112.

29. NuDat2.6. <u>http://www.nndc.bnl.gov/nudat2/</u>. *National Nuclear Data Center*. Brookhaven National Laboratory, NY.

30. Ljungberg M, Strand SE. A Monte Carlo program for the simulation of scintillation camera characteristics. *Comp Meth Progr Biomed.* 1989;29:257-272.

31. Shcherbinin S, Piwowarska-Bilska H, Celler A, Birkenfeld B. Quantitative SPECT/CT reconstruction for 177-Lu and 177-Lu/90-Y targeted radionuclide therapies. *Phys Med Biol.* 2012;57:5733-5747.

32. Segars WP, Sturgeon G, Mendonca S, Grimes J, Tsui BMW. 4D XCAT phantom for multimodality imaging research. *Med Phys.* 2010;37:4902-4915.

33. Brolin G, Gustafsson J, Ljungberg M, Sjögreen Gleisner K. Digital reference phantoms for accuracy assessment of image-based dosimetry in 177Lu peptide receptor radionuclide therapy. *5th International Symposium on Targeted Radionuclide-therapy and Dosimetry (ISTARD)*. Gothenburg, Sweden: European Association of Nuclear Medicine Annual Meeting; October, 18-22, 2014.

34. Dewaraja YK, Frey EC, Sgouros G, et al. MIRD Pamphlet No. 23: Quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. *J Nucl Med.* 2012;53:1310-1325.

35. Lyra M, Ploussi A. Filtering in SPECT Image Reconstruction. *Int J Biomed Imaging*. 2011;2011:693795.

36. Cheng L, Hobbs RF, Segars PW, Sgouros G, Frey EC. Improved dosevolume histogram estimates for radiopharmaceutical therapy by optimizing quantitative SPECT reconstruction parameters. *Phys Med Biol.* 2013;58:3631-3647.

37. Cherry SR, Sorensen JA, Phelps ME. *Physics in Nuclear Medicine (3rd ed)*. Philadelphia, PA: Saunders; 2003.

38. Strand SE, Lamm IL. Theoretical studies of image artifacts and counting losses for different photon fluence rates and pulse-height distributions in single-crystal NaI(Tl) scintillation cameras. *J Nucl Med.* 1980;21:264-275.

39. Delpon G, Ferrer L, Lisbona A, Bardies M. Correction of count losses due to deadtime on a DST-XLi (SmVi-GE) camera during dosimetric studies in patients injected with iodine-131. *Phys Med Biol.* 2002;47:N79-90.

40. Celler A, Piwowarska-Bilska H, Shcherbinin S, Uribe C, Mikolajczak R, Birkenfeld B. Evaluation of dead-time corrections for post-radionuclide-therapy (177)Lu quantitative imaging with low-energy high-resolution collimators. *Nucl Med Commun.* 2014;35:73-87.

41. Koral KF, Zasadny KR, Ackermann RJ, Ficaro EP. Deadtime correction for two multihead Anger cameras in 1311 dual-energy-window-acquisition mode. *Med Phys.* 1998;25:85-91.

42. Shepp LA, Vardi Y. Maximum likelihood reconstruction for emission tomography. *IEEE Trans Med Imaging*. 1982;1:113-122.

43. Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. *IEEE Trans Med Imaging*. 1994;13:601-609.

44. Goetze S, Wahl RL. Prevalence of misregistration between SPECT and CT for attenuation-corrected myocardial perfusion SPECT. *J Nucl Cardiol.* 2007;14:200-206.

45. Dewaraja YK, Frey EC, Sgouros G, et al. MIRD Pamphlet No. 23: Quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. *Journal of Nuclear Medicine*. 2012;53:1310-1325.

46. Ogawa K, Harata Y, Ichihara T, Kubo A, Hashimoto S. A practical method for position-dependent Compton-scatter correction in single photon emission CT. *IEEE Trans Med Imaging*. 1991;10:408-412.

47. de Nijs R, Lagerburg V, Klausen TL, Holm S. Improving quantitative dosimetry in 177Lu-DOTATATE SPECT by energy window-based scatter corrections. *Nucl Med Commun.* 2014;35:522-533.

48. Beauregard JM, Hofman MS, Pereira JM, Eu P, Hicks RJ. Quantitative 177Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system. *Cancer Imaging*. 2011;11:56-66.

49. Zeintl J, Vija AH, Yahil A, Hornegger J, Kuwert T. Quantitative accuracy of clinical 99mTc SPECT/CT using ordered-subset expectation maximization with 3-dimensional resolution recovery, attenuation, and scatter correction. *J Nucl Med.* 2010;51:921-928.

50. Hutton BF, Buvat I, Beekman FJ. Review and current status of SPECT scatter correction. *Phys Med Biol.* 2011;56:R85-112.

51. Frey EC, Tsui BMW. A new method for modeling the spatially-variant, object-dependent scatter response function in SPECT. Paper presented at: Conference Record of the IEEE Nuclear Science and Medical Imaging Symposium, 1996; Anaheim, CA.

52. Frey EC, Ju ZW, Tsui BMW. A fast projector-backprojector pair modeling the asymmetric, spatially varying scatter response function for scatter compensation in SPECT imaging. *IEEE Trans Nucl Sci.* 1993;40:1192-1197.

53. Vandervoort E, Celler A, Harrop R. Implementation of an iterative scatter correction, the influence of attenuation map quality and their effect on absolute quantitation in SPECT. *Phys Med Biol.* 2007;52:1527-1545.

54. Wells RG, Celler A, Harrop R. Analytical calculation of photon distributions in SPECT projections. *IEEE Trans Med Imaging*. 1998;45:3202-3214.

55. Erlandsson K, Buvat I, Pretorius PH, Thomas BA, Hutton BF. A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology. *Phys Med Biol.* 2012;57:R119-159.

56. Uribe C, Celler A, Beauregard JM. Planar vs. tomographic determination of normalization factors for absolute quantitation of SPECT/CT studies. *Eur J Nucl Med Mol Imaging*. 2014;41:331.

57. Ilan E, Sandstrom M, Wassberg C, et al. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. *J Nucl Med.* 2015;56:177-182.

58. Uribe C, Celler A, Frauenstein L, et al. Accuracy of Lu-177 quantitation for dosimetry in patients undergoing neuro-endocrine tumors radionuclide therapy *Eur J Nucl Me Mol Imaging*. 2014;41:S332.

59. Vennart J. ICRP Publication 30: Limits for intakes of radionuclides by workers. *Ann ICRP*. 1981;6:85-87.

60. Valkema R, Pauwels SA, Kvols LK, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. *J Nucl Med.* 2005;46 Suppl 1:83S-91S.

61. Swärd C, Bernhardt P, Ahlman H, et al. [177Lu-DOTA 0-Tyr 3]octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney. *World J Surg.* 2010;34:1368-1372.

62. Garske U, Sandstrom M, Johansson S, et al. Minor changes in effective half-life during fractionated 177Lu-octreotate therapy. *Acta Oncol.* 2012;51:86-96.

63. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. *J Nucl Med.* 2005;46:1023-1027.

64. Sjogreen K, Ljungberg M, Wingardh K, Minarik D, Strand SE. The LundADose method for planar image activity quantification and absorbed-dose assessment in radionuclide therapy. *Cancer Biother Radiopharm.* 2005;20:92-97.

65. Sjögreen Gleisner K, Ljungberg M. Patient-specific whole-body attenuation correction maps from a CT system for conjugate-view-based activity quantification: method development and evaluation. *Cancer Biother Radiopharm.* 2012;27:652-664.

66. Sjogreen-Gleisner K, Rueckert D, Ljungberg M. Registration of serial SPECT/CT images for three-dimensional dosimetry in radionuclide therapy. *Phys Med Biol.* 2009;54:6181-6200.

67. Gustafsson J, Nilsson P, Gleisner KS. On the biologically effective dose (BED)-using convolution for calculating the effects of repair: II. Numerical considerations. *Phys Med Biol.* 2013;58:1529-1548.

68. Eckerman KF, Endo A. *MIRD: Radionuclide data and decay schemes, 2nd edition.* Reston, VA; 2008.

69. Grimes J, Celler A, Shcherbinin S, Piwowarska-Bilska H, Birkenfeld B. The accuracy and reproducibility of SPECT target volumes and activities estimated using an iterative adaptive thresholding technique. *Nucl Med Commun.* 2012;33:1254-1266.




FIGURE 1: Simulated energy spectra of 7.4 GBq ¹⁷⁷Lu distributed in the XCAT phantom imaged with LEGP and ME collimators (GE Infinia). Solid lines represent the total spectra, while dashed lines show the spectra of primary photons that pass unscattered through the phantom and the collimator. Dotted lines indicate 20% energy windows centered at 113 keV and 208 keV photopeaks. Note the difference (due to photon scatter and collimator septal penetration) in both the shape of the spectra and in their count rates.




FIGURE 2: Simulated projections of ¹⁷⁷Lu distributed in the XCAT phantom showing the difference in image quality obtained with LEGP and ME collimators (GE Infinia) and two energy windows (113 keV and 208 keV). (A) LEGP and 113 keV window. (B) ME and 113 keV window. (C) LEGP and 208 keV window. (D) ME and 113 keV window.




FIGURE 3: Simulated projection images of the XCAT phantom corresponding to a typical ¹⁷⁷Lu-Dotatate imaging study at 24h post injection. (A) Image simulated by assuming a scintillation camera with "perfect" spatial resolution and no attenuation and scatter in the phantom. Since no interactions occur this image is representative for both the 113 keV and the 208 keV energy window. (B) Image simulated with ME collimator (GE Infinia), photon attenuation and scatter included and with a realistic noise level for a 20 % energy window centered on 113 keV. (C) Image shows the same as for (B) but for a 20 % energy window centered on 208 keV. (D) Image showing the sum of the two images shown in (B) and (C).




FIGURE 4. The total activity in VOIs normalized to the highest activity obtained for the particular VOI for different number of OSEM updates. Reconstructions included compensations for attenuation, scatter and collimator response. The analysis was performed using VOIs delineated in consecutive slices over the kidneys and the tumor in a patient study.




FIGURE 5. A row of images showing a comparison of the true scatter distributions (A and C) from ¹⁷⁷Lu photons and those estimated by the TEW scatter compensation method (B and D) for the 113-keV energy window (A and B) and for the 208-keV (C and D) energy window (20%). Scatter distributions were simulated using the XCAT phantom and the settings for the scatter windows for the TEW method were [lw=88-102, uw=125-153] keV for 113keV photopeak and [lw=153-187] keV for the 208-keV photopeak. The upper TEW window for 208-keV photo peak was set to zero because of very few scatter events and the contribution from the 249 keV photon from the ¹⁷⁷Lu decay. Collimators parameters represent a GE Infinia camera.




FIGURE 6. OSEM reconstructed images (80 OSEM updates) from a ¹⁷⁷Lu-Dotatate patient study measured at 24 h post-injection. (A) no corrections. (B) attenuation correction only. (C) attenuation and collimator compensation corrections. (D) attenuation, ESSE-scatter and collimator response compensation. No post-filtering has been applied.




FIGURE 7. A reconstructed image (80 OSEM updates) from a ¹⁷⁷Lu-Dotatate patient study measured at 24 h post-injection with attenuation, scatter (ESSE) and collimator response compensation. A ROI over the right kidney is indicated. The small hot region is a tumor. To the right the TAC curve shows calculated dose-rate as a function of time. The arrow indicates the time where the SPECT study was performed.

TABLE 1 A compilation of energies and intensities of γ -ray emissions (%) per nuclear decay of ¹⁷⁷Lu. The values in bold are recommended for use in this work.

keV	Ref (25)	Ref (24) ¹	Ref (26)	Ref (<i>68</i>)	Ref (28)	Ref (23,29)
71.6	0.1734	0.1844	0.1720	0.154	0.1726	0.172
112.9	6.17	6.44	6.22	6.40	6.20	6.17
136.7	0.0464	0.0563	0.0492	0.0480	0.0470	0.0469
208.4	10.36	10.36	10.55	11.0	10.38	10.36
249.7	0.1987	0.2053	0.2023	0.212	0.2012	0.2008
321.3	0.2074	0.2559	0.2111	0.219	0.216	0.210

¹⁾ Intensities are calculated based on (22) where normalization assuming 208 keV photopeak intensity of 100 was used.

TABLE 2

Simulated (NEMA) system sensitivity per camera detector (cps/MBq)_{FOV} for two ¹⁷⁷Lu photopeaks and a number of imaging conditions. The fractions of the detected counts that are due to collimator scatter and septal penetration are shown in parentheses. Note that some contribution to the 113 keV window comes from events from 208 keV photons Compton-scattered in the crystal followed by an escape. This contribution increases with decreasing crystal thickness.

			solution gold your			
		113-keV Window		208-keV Window		
Crystal	Collimator ¹⁾	15%	20%	15%	20%	
3/8"	HE	6.8 (3.0%)	7.5 (3.1%)	7.0 (6.8%)	7.2 (6.9%)	
3/8"	ME	5.8 (3.3%)	6.3 (3.5%)	6.0 (7.8%)	6.1 (8.0%)	
3/8"	LEGP	16.1 (31.8%)	18.6 (35.4%)	71.5 (84.7%)	74.6 (84.9%)	
3/8"	LEHR	12.0 (43.5%)	14.3 (47.9%)	70.3 (90.4%)	73.2 (90.5%)	
5/8"	HE	6.7 (2.9%)	7.3 (2.9%)	9.5 (6.9%)	9.8 (7.0%)	
5/8"	ME	5.7 (3.2%)	6.2 (3.3%)	8.1 (7.8%)	8.3 (7.9%)	
5/8"	LEGP	14.1 (22.7%)	16.0 (26.0%)	95.1 (84.4%)	98.6 (84.5%)	
5/8"	LEHR	9.9 (32.3%)	11.4 (36.1%)	92.9 (90.1%)	96.6 (90.3%)	

¹⁾GE Infinia camera

TABLE 3

Ratios of scattered photons to the total number of photons detected within the energy window (15% or 20%). The results of this simulation with the XCAT phantom are presented as a function of two crystal thicknesses and four collimators.

		113 keV Window		208 keV Window	
Crystal	Collimator ¹⁾	15%	20%	15%	20%
3/8"	HE	0.60	0.55	0.27	0.22
3/8"	ME	0.60	0.55	0.27	0.22
3/8"	LEGP	0.53	0.49	0.21	0.18
3/8"	LEHR	0.49	0.47	0.20	0.17
5/8"	HE	0.60	0.56	0.27	0.22
5/8"	ME	0.60	0.56	0.26	0.22
5/8"	LEGP	0.55	0.52	0.20	0.17
5/8"	LEHR	0.53	0.49	0.20	0.17

¹⁾GE Infinia camera

TABLE 4

Recent phantom experiments evaluating accuracy of quantification of ¹⁷⁷Lu activity.

Ref.	Photopeak energy	Phantom	Reconstruction	Segmentation	Accuracy
(48)	208 keV	Three 175 mL cylinders in cold water	OSEM, CDR, AC, DEW-SC	40% fixed threshold	<15% for cylinders <9.5% for total phantom activity
(31)	113 keV	70 mL cylinder placed in air and cold water	OSEM, CDR, AC, APDI-SC	CT-volume augmented by 4 voxels in each direction	1-2% for cylinder VOI <11-18% for total phantom activity
(58)		0.5–113 mL spheres in air, cold and hot water	OSEM, CDR, AC, TEW-SC		<3% for spheres >1ml in air <13% for spheres >1ml in water <3% for 113mL sphere in hot water
		8.5–34 mL bottles in air and cold water	OSEM, CDR, AC, TEW-SC	Fixed threshold 0.1% for air, 1% for water, IADT (<i>69</i>) for hot water	<5% in air <13% in water
	208 keV	Four 34 mL cylinders in thorax phantom (non- uniform cold environment)	OSEM, CDR, AC, APDI-SC		<5%
		34–148 mL cylinders in air and between cold water bags	OSEM,CDR, AC, TEW-SC		<7%
(47)	208 ko)/	27 mL spherical	OSEM, CDR, AC		
	208 keV	insert in NEMA Phantom	TEW (15%) TEW (20%) ESSE		11% 12% 7%